Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Inhaled Nitric Oxide for PAH
NCT02652429Phase 3Unknown
- Sponsor
- Bellerophon Therapeutics
- Start
- Mar 2016
- Primary completion
- Apr 2023
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of nitric oxide in pulmonary arterial hypertension (PAH), sponsored by Bellerophon Therapeutics. Primary endpoints: Incidence of Serious Adverse Events and Incidence of INOpulse device malfunction and/or device failure leading to an AE. Status: unknown.
02
Drugs
nitric oxide
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02652429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652429.